Search NLS News

The story of Finnish biotechnology is not a straightforward success story. It is a story of an ambitious start, of setbacks, and of stubborn rebuilding – and of what happens when a field that demands patience meets short-term expectations. As Finnish Bioindustries turns 20, it is a good moment to look back.

Elicera Therapeutics has received a Notice of Allowance from the Japan Patent Office (JPO) for its patent application covering the oncolytic virus candidate ELC-201 in solid tumors.

Uppsala-based Readily Diagnostics has received a grant of approximately USD 970,000 (about SEK 9 million) from the Gates Foundation to develop a low-cost point-of-care test for chlamydia, gonorrhea and trichomoniasis, aimed at low-resource settings.

The US FDA has approved RASONQUE (daraxonrasib), Revolution Medicines' once-daily pill, for adults with previously treated metastatic pancreatic adenocarcinoma — the first medicine to directly target RAS, the protein driving most pancreatic cancers.

Niels Abel Bonde highlights his positive experience from working in the Medicon Valley region in a LinkedIn post, including more than six years as General Manager for Novo Nordisk Sweden with office in Malmö.

NordicRWE has established offices in Sweden and Denmark alongside its Oslo base, aiming to make it easier to run health data studies across the whole Nordic region – particularly in cancer, where precision medicine is splitting patients into ever-smaller subgroups.

Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible Canadian patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, BioArctic's partner Eisai announced. The Swedish biotech invented the antibody and holds commercialisation rights to it in the Nordic region.

Rickard Brånemark, Chief Medical and Scientific Officer at Integrum, has traveled to Ukraine eight times to train surgeons in an advanced Swedish implant technology for amputees. The need, he writes, is difficult to overstate – and the question now is how quickly the technology can be scaled up to meet it.

The company has entered a binding term sheet with BioMarin Pharmaceutical to settle all litigation over YUVIWEL (navepegritide), with BioMarin granting Ascendis a non-exclusive, worldwide, royalty-bearing license to continue developing and selling the drug without restriction.

The company reported H1 2026 sales revenue up 35.2 percent year-on-year, alongside new data on its psoriasis drug candidate HRO350 that it says complement earlier results from its HeROPA trial.